Abstract

Many polycyclic marine alkaloids are thought to derive from partly reduced macrocyclic alkylpyridine derivatives via a transannular Diels–Alder reaction that forms their common etheno-bridged diaza-decaline core (“Baldwin–Whitehead hypothesis”). Rather than trying to emulate this biosynthesis pathway, a route to these natural products following purely chemical logic was pursued. Specifically, a Michael/Michael addition cascade provided rapid access to this conspicuous tricyclic scaffold and allowed different handles to be introduced at the bridgehead quarternary center. This flexibility opened opportunities for the formation of the enveloping medium-sized and macrocyclic rings. Ring closing alkyne metathesis (RCAM) proved most reliable and became a recurrent theme en route to keramaphidin B, ingenamine, xestocyclamine A, and nominal njaoamine I (the structure of which had to be corrected in the aftermath of the synthesis). Best results were obtained with molybdenum alkylidyne catalysts endowed with (tripodal) silanolate ligands, which proved fully operative in the presence of tertiary amines, quinoline, and other Lewis basic sites. RCAM was successfully interlinked with macrolactamization, an intricate hydroboration/protonation/alkyl-Suzuki coupling sequence, or ring closing olefin metathesis (RCM) for the closure of the second lateral ring; the use of RCM for the formation of an 11-membered cycle is particularly noteworthy. Equally rare are RCM reactions that leave a pre-existing triple bond untouched, as the standard ruthenium catalysts are usually indiscriminative vis-à-vis the different π-bonds. Of arguably highest significance, however, is the use of two consecutive or even concurrent RCAM reactions en route to nominal njaoamine I as the arguably most complex of the chosen targets.

Highlights

  • In a recent Communication we reported the first total syntheses of ingenamine and nominal xestocyclamine A.1These polycyclic alkaloids had originally been proposed to be “pseudoenantiomeric” to each other, differing in the exact positioning of the double bond embedded into the 11membered ring (Scheme 1).[2−4] Our data, provided compelling evidence that the originally assigned structure of xestocyclamine A needs to be corrected in exactly this detail: natural xestocyclamine A ((−)-2) and ingenamine ((+)-2) are almost certainly true enantiomers.[1]At the meta-level, this conclusion is not all that surprising in view of the proposed biosynthesis of these and related alkaloids

  • It has long been speculated that the gambit of the famous “Baldwin−Whitehead pathway” might not be enzymedependent:[5,6] it consists of a transannular Diels−Alder reaction of a partly reduced macrocyclic dipyridine derivative of type A, which affords the enantiomeric iminium ions B and ent-B in the first place; reduction leads to keramaphidin B (1), which occurs in nature in both enantiomeric forms.[4,7−9] this observation strongly suggests that the initial [4 +

  • One might want to revisit the choice of the allyl ester: the palladiumcatalyzed decarboxylative allylation worked perfectly well in terms of yield and selectivity, this reaction is limiting in conceptual terms, as it does not allow other substituents to be attached to the bridgehead position. This handicap had already surfaced in our original campaign: while the allyl handle was ideal for the synthesis of nominal xestocyclamine A ((−)-3) via hydroboration/cross coupling, a stepwise transposition of the double bond by hydroboration/oxidation and subsequent Wittig olefination with formation of 12 was necessary on the way to actual xestocyclamine A ((−)-2).[1]

Read more

Summary

A Unified Approach to Polycyclic Alkaloids of the Ingenamine Estate

Spohr,† Sandra Tobegen, Christophe Fares , and Alois Fürstner*. Downloaded via 107.23.70.80 on November 8, 2021 at 12:34:10 (UTC). See https://pubs.acs.org/sharingguidelines for options on how to legitimately share published articles

■ INTRODUCTION
■ CONCLUSIONS
■ ACKNOWLEDGMENTS
■ REFERENCES
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call